Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
Study sponsor: Vaxcyte, Inc. · PCVX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-02-15Actual
Enrollment · participants207Actual
Source updated2024-10-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.